Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review)

Schirrmacher,Volker

doi:10.3892/ijmm.2015.2213

Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review)

Authors:
- Volker Schirrmacher
View Affiliations

Affiliations: Division of Tumorimmunology, The Immunological and Oncological Center of Cologne, D‑50674 Cologne, Germany
Published online on: May 18, 2015 https://doi.org/10.3892/ijmm.2015.2213
Pages: 3-10

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this review, two types of RNA viruses are compared with regard to the type I interferon (IFN) response in order to obtain a better understanding of the molecular mechanisms of immune activation or evasion. Upon human infection, both viruses exert either beneficial or detrimental effects. The Newcastle disease virus (NDV), is a type strain for avian paramyxoviruses, while the Ebola virus (EBOV), is a virus affecting primates. During evolution, both viruses specifically adapted to their respective hosts, acquiring sophisticated viral escape mechanisms. Two types of receptors play an important role in the life cycle of these two viruses: cytoplasmic retinoic acid‑inducible gene I (RIG‑I) and membrane expressed type I IFN receptor (IFNAR). In mouse and human cells, NDV is a strong inducer of the type I IFN response. The early phase of this is initiated by signaling through RIG‑I and the late response by signaling through IFNAR. EBOV does not induce type I IFN responses in humans as it has viral proteins that specifically and strongly interfere with RIG‑I and IFNAR signaling, as well as immune activation. In this review, we discuss whether the beneficial effects of one virus can be exploited in the fight against the detrimental effects of the other.

View Figures

View References

1	Pestka S, Krause CD and Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 202:8–32. 2004. View Article : Google Scholar : PubMed/NCBI
2	Levy DE and García-Sastre A: The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12:143–156. 2001. View Article : Google Scholar : PubMed/NCBI
3	González-Navajas JM, Lee J, David M and Raz E: Immunomodulatory functions of type I interferons. Nat Rev Immunol. 12:125–135. 2012.PubMed/NCBI
4	Kadowaki N, Antonenko S, Lau JY and Liu YJ: Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med. 192:219–226. 2000. View Article : Google Scholar : PubMed/NCBI
5	Taniguchi T, Mantei N, Schwarzstein M, et al: Human leukocyte and fibroblast interferons are structurally related. Nature. 285:547–549. 1980. View Article : Google Scholar : PubMed/NCBI
6	Shuai K and Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 3:900–911. 2003. View Article : Google Scholar : PubMed/NCBI
7	Barber GN: Host defense, viruses and apoptosis. Cell Death Differ. 8:113–126. 2001. View Article : Google Scholar : PubMed/NCBI
8	Jarvis ED, Mirarab S, Aberer AJ, Li B, Houde P, Li C, Ho SY, Faircloth BC, Nabholz B, Howard JT, et al: Whole-genome analyses resolve early branches in the tree of life of modern birds. Science. 346:1320–1331. 2014. View Article : Google Scholar : PubMed/NCBI
9	Alexander DJ: Newcastle Disease. Kluwer Academic Publishers; Boston, MA: 1988, View Article : Google Scholar
10	Schirrmacher V and Fournier P: Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer (Review). Methods Mol Biol. 542:565–605. 2009. View Article : Google Scholar
11	Fournier P and Schirrmacher V: Oncolytic Newcastle Disease Virus as cutting edge between tumor and host. Biology (Basel). 2:936–975. 2013.
12	Hanson RP and Brandly CA: Identification of vaccine strains of Newcastle disease virus. Science. 122:156–157. 1955.PubMed/NCBI
13	Mebatsion T, de Vaan LT, de Haas N, Römer-Oberdörfer A and Braber M: Identification of a mutation in editing of defective Newcastle disease virus recombinants that modulates P-gene mRNA editing and restores virus replication and pathogenicity in chicken embryos. J Virol. 77:9259–9265. 2003. View Article : Google Scholar : PubMed/NCBI
14	Huang Z, Krishnamurthy S, Panda A and Samal SK: Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol. 77:8676–8685. 2003. View Article : Google Scholar : PubMed/NCBI
15	Park MS, Shaw ML, Muñoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, García-Sastre A and Basler CF: Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 77:1501–1511. 2003. View Article : Google Scholar :
16	Park MS, García-Sastre A, Cros JF, Basler CF and Palese P: Newcastle disease virus V protein is a determinant of host range restriction. J Virol. 77:9522–9532. 2003. View Article : Google Scholar : PubMed/NCBI
17	Horvath CM: Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem. 271:4621–4628. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hengel H, Koszinowski UH and Conzelmann KK: Viruses know it all: new insights into IFN networks. Trends Immunol. 26:396–401. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zaslavsky E, Hershberg U, Seto J, Pham AM, Marquez S, Duke JL, Wetmur JG, Tenoever BR, Sealfon SC and Kleinstein SH: Antiviral response dictated by choreographed cascade of transcription factors. J Immunol. 184:2908–2917. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wilden H, Fournier P, Zawatzky R and Schirrmacher V: Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol. 34:971–982. 2009.PubMed/NCBI
21	Fournier P, Wilden H and Schirrmacher V: Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol. 40:287–298. 2012.
22	Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, et al: 5′-Triphosphate RNA is the ligand for RIG-I. Science. 314:994–997. 2006. View Article : Google Scholar : PubMed/NCBI
23	Taniguchi T and Takaoka A: The interferon-alpha/beta system in antiviral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol. 14:111–116. 2002. View Article : Google Scholar : PubMed/NCBI
24	Wilden H, Schirrmacher V and Fournier P: Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. Int J Oncol. 39:493–504. 2011.PubMed/NCBI
25	Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J, et al: Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature. 514:372–375. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhang X, Li S, Luo Y, Chen Y, Cheng S, Zhang G, Hu C, Chen H and Guo A: Mycobacterium bovis and BCG induce different patterns of cytokine and chemokine production in dendritic cells and differentiation patterns in CD4⁺ T cells. Microbiology. 159:366–379. 2013. View Article : Google Scholar
27	Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R and Hiscott J: Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol. 76:5532–5539. 2002. View Article : Google Scholar : PubMed/NCBI
28	Sen GC and Peters GA: Viral stress-inducible genes. Adv Virus Res. 70:233–263. 2007. View Article : Google Scholar : PubMed/NCBI
29	Tailor P, Tamura T and Ozato K: IRF family proteins and type I interferon induction in dendritic cells. Cell Res. 16:134–140. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ivashkiv LB and Donlin LT: Regulation of type I interferon responses. Nat Rev Immunol. 14:36–49. 2014. View Article : Google Scholar :
31	Parks GD and Alexander-Miller MA: Paramyxovirus activation and inhibition of innate immune responses. J Mol Biol. 425:4872–4892. 2013. View Article : Google Scholar : PubMed/NCBI
32	Fournier P, Arnold A, Wilden H and Schirrmacher V: Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol. 40:840–850. 2012.
33	Fournier P, Arnold A and Schirrmacher V: Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON. 14(Suppl): S111–S122. 2009.
34	Weber F, Kochs G and Haller O: Inverse interference: how viruses fight the interferon system. Viral Immunol. 17:498–515. 2004. View Article : Google Scholar
35	Jenner RG and Young RA: Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol. 3:281–294. 2005. View Article : Google Scholar : PubMed/NCBI
36	Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, Lander ES and Hacohen N: The plasticity of dendritic cell responses to pathogens and their components. Science. 294:870–875. 2001. View Article : Google Scholar : PubMed/NCBI
37	Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence. Int J Cancer. 119:328–338. 2006. View Article : Google Scholar : PubMed/NCBI
38	Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V and Momburg F: Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol. 83:8108–8121. 2009. View Article : Google Scholar : PubMed/NCBI
39	Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V and Walczak H: TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol. 170:1814–1821. 2003. View Article : Google Scholar : PubMed/NCBI
40	Termeer CC, Schirrmacher V, Bröcker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 7:316–323. 2000. View Article : Google Scholar : PubMed/NCBI
41	Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol. 23:2592–2596. 1993. View Article : Google Scholar : PubMed/NCBI
42	Umansky V, Shatrov VA, Lehmann V and Schirrmacher V: Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol. 8:491–498. 1996. View Article : Google Scholar : PubMed/NCBI
43	Klenk HD: Marburg and Ebola Viruses. Current Topics in Microbiol and Immunol 235. Springer; 1999
44	Bray M and Geisbert TW: Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 37:1560–1566. 2005. View Article : Google Scholar : PubMed/NCBI
45	WHO Ebola Response Team: Ebola virus disease in West Africa. New Engl J Med. 371:1481–1495. 2014. View Article : Google Scholar
46	Zhang L, Wang H and Zhang YQ: Against Ebola: Type I interferon guard risk and mesenchymal stromal cell combat sepsis. J Zhejiang Univ Sci B. 16:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
47	Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF and Leung DW: Filoviral immune evasion mechanisms. Viruses. 3:1634–1649. 2011. View Article : Google Scholar : PubMed/NCBI
48	Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB and Amarasinghe GK: Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci USA. 106:411–416. 2009. View Article : Google Scholar : PubMed/NCBI
49	Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, et al: Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 16:187–200. 2014. View Article : Google Scholar : PubMed/NCBI
50	Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, Kunert J, Kroon GJ, Kawaoka Y, MacRae IJ, et al: Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog. 8:e10029162012. View Article : Google Scholar : PubMed/NCBI
51	Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, et al: Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol. 17:165–172. 2010. View Article : Google Scholar : PubMed/NCBI
52	Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, Klenk HD, Palese P and García-Sastre A: The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 77:7945–7956. 2003. View Article : Google Scholar : PubMed/NCBI
53	Feng Z, Cerveny M, Yan Z and He B: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol. 81:182–192. 2007. View Article : Google Scholar :
54	Hartman AL, Ling L, Nichol ST and Hibberd ML: Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol. 82:5348–5358. 2008. View Article : Google Scholar : PubMed/NCBI
55	Zhang AP, Bornholdt ZA, Liu T, Abelson DM, Lee DE, Li S, Woods VL Jr and Saphire EO: The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 8:e10025502012. View Article : Google Scholar : PubMed/NCBI
56	Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, et al: Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol. 88:13990–14001. 2014. View Article : Google Scholar : PubMed/NCBI
57	Cervantes-Barragán L, Kalinke U, Züst R, König M, Reizis B, López-Macías C, Thiel V and Ludewig B: Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 182:1099–1106. 2009. View Article : Google Scholar : PubMed/NCBI
58	Ayllon J and García-Sastre A: The NS1 protein: A multitasking virulence factor. Curr Top Microbiol Immunol. 386:73–107. 2015.
59	Reder AT, Oger JF, Kappos L, O’Connor P and Rametta M: Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. 3:294–302. 2014. View Article : Google Scholar
60	Corti D and Lanzavecchia A: Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 31:705–742. 2013. View Article : Google Scholar : PubMed/NCBI
61	Corti D, Sallusto F and Lanzavecchia A: High throughput cellular screens to interrogate the human T and B cell repertoires. Curr Opin Immunol. 23:430–435. 2011. View Article : Google Scholar : PubMed/NCBI
62	Sobarzo A, Eskira Y, Herbert AS, Kuehne AI, Stonier SW, Ochayon DE, Fedida-Metula S, Balinandi S, Kislev Y, Tali N, et al: Immune memory to Sudan virus: Comparison between two separate disease outbreaks. Viruses. 7:37–51. 2015. View Article : Google Scholar : PubMed/NCBI
63	Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, et al: Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA. 110:1893–1898. 2013. View Article : Google Scholar : PubMed/NCBI
64	Barber GN: VSV-tumor selective replication and protein translation. Oncogene. 24:7710–7719. 2005. View Article : Google Scholar : PubMed/NCBI